Floatz logo

Jab-2485

ER+ Breast Cancer

Jacobio Pharmaceuticals Co., Ltd.Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

76 Active assets in the ER+ Breast Cancer cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Everolimus
UNC Lineberger Comprehensive Cancer Center
Phase 4BBB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB
Capivasertib
Imperial College London
Phase 2BB

View all 50 →

Same molecule, other indications

Jab-2485 is also rated in:

triple-negative breast carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
ARID1A Gene MutationDormant
CCC
Indicative ·
48 / 100
View asset →
small cell lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →